2018 American Transplant Congress
Single Reduced Dose Thymoglobuline as Induction in Kidney Retransplant
Hospital do Rim, São Paulo, Brazil.
IntroductionKidney retransplant is a high risk procedure, without a consensus about the best induction imunnossupression strategy. Only a few studies have evaluated these growing proportion…2018 American Transplant Congress
Basiliximab Induction in HIV-Positive Renal Transplant Recipients Compared to an HIV-Negative Cohort
Purpose: There is an elevated risk of acute rejection in HIV+ renal transplant recipients and continued evaluation of the most appropriate induction therapy remains. Use…2018 American Transplant Congress
A Meta-Analysis for Induction Therapy of Kidney Transplantation: Comparison of Antithymocyte Globulin and Interleukin 2 Receptor Antagonist
Objectives To compare the efficacy and safety of antithymocyte globulin (ATG) and interleukin 2 receptor antagonist (IL2Ra) in induction therapy of kidney transplantation.Method A literature…2018 American Transplant Congress
Improved Value with Individualized Antithymocyte Globulin Dosing Protocol in Renal Transplant
University of Virginia Healthsystem, Charlottesville, VA.
Medication costs represent one of the largest costs associated with transplantation. With growing pressure to reduce health care costs while maintaining excellent outcomes, this study…2018 American Transplant Congress
Basiliximab Induction in Simultaneous Liver-Kidney Transplant
The Johns Hopkins Hospital, Baltimore.
Rabbit anti-thymocyte globulin (rATG) is the most common induction agent in renal transplant recipients; however, induction agent selection for SLK recipients is not well described.…2018 American Transplant Congress
Outcomes Associated with Rabbit Anti-Thymocyte Globulin Induction According to Mg/Kg of Total Body Weight in Kidney Transplant Recipients
Pharmacy, Tampa General Hospital, Tampa, FL.
Purpose: The optimal dosing weight used for rabbit anti-thymocyte globulin (rATG) induction therapy in transplantation continues to lack a consensus. The impact of alternative dosing…2018 American Transplant Congress
Novel Low Dosing of Rabbit Antithymocyte Globulin Preserves Excellent Outcomes and Improves the Value of Care in Low Risk Renal Transplantation
University of Virginia Health System, Charlottesville, VA.
Elderly and non-sensitized renal transplant patients may benefit from lesser induction immunosuppression. This study evaluates three year clinical outcomes of a low risk renal transplant…2018 American Transplant Congress
Survey of Rabbit Anti-Thymocyte Globulin Usage for Kidney Transplant Induction Therapy in the United States
Background: Rabbit anti-thymocyte globulin (rATG) has become the most widely used induction agent in kidney transplantation (KTx) and has recently received FDA approval for this…2018 American Transplant Congress
The Efficacy and Safety of Rituximab as Induction Therapy in Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials
Objectives. This meta-analysis was undertaken to assess the efficacy and safety of rituximab as induction therapy in kidney transplantation.Methods. OVID, Embase, SCI, PubMed and EBSCO…2018 American Transplant Congress
Rhesus-Specific Anti-Thymocyte Globulin as an Adjuvant to Costimulatory-Blockade-Based Immunotherapy
Background Belatacept targets de novo alloimmune responses with minimal off target effects in renal transplantation, though adjuvant therapy is required to control costimulation-blockade resistant rejection…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 31
- Next Page »